A number of firms have modified their ratings and price targets on shares of Alimera Sciences (NASDAQ: ALIM) recently:

  • 8/4/2017 – Alimera Sciences was given a new $5.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 8/3/2017 – Alimera Sciences was given a new $3.00 price target on by analysts at Cowen and Company. They now have a “buy” rating on the stock.
  • 7/27/2017 – Alimera Sciences was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 7/26/2017 – Alimera Sciences was given a new $5.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 7/25/2017 – Alimera Sciences was given a new $3.00 price target on by analysts at Cowen and Company. They now have a “buy” rating on the stock. They wrote, “Positive Iluvien results were published in the journal Eye” for the treatment of DME.””
  • 7/13/2017 – Alimera Sciences was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 7/13/2017 – Alimera Sciences was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. “
  • 7/11/2017 – Alimera Sciences was given a new $5.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 7/11/2017 – Alimera Sciences had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $3.00 price target on the stock. They wrote, “Alimera has amended its agreement with pSivida to expand Iluvien’s indication in.””
  • 7/10/2017 – Alimera Sciences was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $1.50 price target on the stock. According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. “
  • 6/13/2017 – Alimera Sciences was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness. “

Shares of Alimera Sciences, Inc. (NASDAQ:ALIM) opened at 1.56 on Tuesday. The company’s market capitalization is $101.25 million. Alimera Sciences, Inc. has a 1-year low of $1.03 and a 1-year high of $2.40. The company’s 50-day moving average price is $1.42 and its 200-day moving average price is $1.38.

Alimera Sciences (NASDAQ:ALIM) last issued its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The business had revenue of $10.40 million during the quarter, compared to analyst estimates of $10.20 million. During the same period last year, the firm posted ($0.17) earnings per share. Alimera Sciences’s quarterly revenue was up 8.3% compared to the same quarter last year. On average, equities analysts expect that Alimera Sciences, Inc. will post ($0.21) earnings per share for the current fiscal year.

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Receive News & Ratings for Alimera Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.